Fosun Pharma and Kite unveil plans for JV

19 January 2017

Shanghai Fosun Pharmaceutical (HK: 02196) and the USA’s Kite Pharma (Nasdaq: KITE) unveiled their plan for the joint venture they are about to establish at a press meeting on Monday in Shanghai, where the JV will be located.

The priority for the JV will be bringing China KTE-C19, a CAR T cell therapy targeting the antigen CD19 that aims to curenon-Hodgkin lymphoma (NHL)through just one injection, reports The Pharma Letter’s local correspondent Wang Fangqing.

“We will start to apply for clinical studies in China as soon as the technologies are transferred. It shouldn’t take too much time,” Wu Yifang, Fosun Pharma’s president, told The Pharma Letter. He said the facility is already in place as it will be located in Fosun’s existing innovation incubator in Zhangjiang high tech zone, which is home to many multinationals’ China operations, including Roche and AstraZeneca.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK